TAK-475

TAK-475

Application

TAK-475 has been used:as a farnesyl-diphosphate farnesyltransferase 1 (FDFT1) inhibitor to study its effects on cell signaling in pancreatic ductal adenocarcinoma cellsas a squalene synthase (SQS) inhibitor to stabilize HMG-CoA reductase (HMGCR)-dCat-ELuc proteinsas an SQS inhibitor to study its effects on the migration of prostate cancer cells

Biochem/physiol Actions

TAK-475 (Lapaquistat acetate) is a potent and selective squalene synthase inhibitor. TAK-475 effectively lowers low-density lipoprotein cholesterol in human. Clinical development of TAK-475 was discontinued due to hepatotoxicity seen in two patients receiving a high dose.

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour InChI key InChI Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3575908 TAK-475 white to beige CMLUGNQVANVZHY-POURPWNDSA-N 1S/C33H41ClN2O9/c1-20(37)44-19-33(2,3)18-36-25-10-9-22(34)16-24(25)30(23-7-6-8-26(42-4)31(23)43-5)45-27(32(36)41)17-28(38)35-13-11-21(12-14-35)15-29(39)40/h6-1 SIGMA-ALDRICH −20°C DMSO: 2 mg/mL, clear powder ≥98% (HPLC)
£817.61 (exc VAT) per 25MG
-
+
3575909 TAK-475 white to beige CMLUGNQVANVZHY-POURPWNDSA-N 1S/C33H41ClN2O9/c1-20(37)44-19-33(2,3)18-36-25-10-9-22(34)16-24(25)30(23-7-6-8-26(42-4)31(23)43-5)45-27(32(36)41)17-28(38)35-13-11-21(12-14-35)15-29(39)40/h6-1 SIGMA-ALDRICH −20°C DMSO: 2 mg/mL, clear powder ≥98% (HPLC)
£208.93 (exc VAT) per 5MG
-
+